The BAROSTIM NEO® System is indicated for the improvement of symptoms of heart failure—quality of life, six-minute hall walk and functional status—for patients who remain symptomatic despite treatment with guideline-directed medical therapy with:
- NYHA Class III or Class II (who had a recent history of Class III)
- Left ventricular ejection fraction ≤ 35%
- NT-proBNP < 1600 pg/ml
Excluding patients indicated for Cardiac Resynchronization Therapy (CRT) according to AHA/ACC/ESC guidelines.